Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554410 · ClinicalTrials.gov registry record · Phase 1
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01554410 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 35 participants.
The verdict
NCT01554410, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary objective of the study is to identify the highest dose of gemcitabine that can be given safely with cisplatin and pelvic intensity modulated radiation therapy (IMRT) in women with locally advanced cervical cancer. The investigators hypothesis is that IMRT will reduce gastrointestinal and hematologic toxicity, permitting escalating doses of gemcitabine to be feasibly delivered in patients with locally advanced cervical cancer.
Interventions
- DRUG Cisplatin
- RADIATION Intensity Modulated Radiation Therapy (IMRT)
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554410
The ClinicalTrials.gov registry entry for NCT01554410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01554410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554410 about?
NCT01554410 is a clinical study titled "Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma". The primary objective of the study is to identify the highest dose of gemcitabine that can be given safely with cisplatin and pelvic intensity modulated radiation therapy (IMRT) in women with locally advanced cervical cancer. The investigators hypothesis is that IMRT will reduce gastrointestinal and...
What is the current status of trial NCT01554410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT01554410?
The interventions under investigation include: Cisplatin (DRUG), Intensity Modulated Radiation Therapy (IMRT) (RADIATION), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01554410?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.